Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin’s lymphoma; symptom burden and quality of life

Authors

  • Siri A. Eikeland National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway
  • Knut B. Smeland National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology, Oslo University Hospital, Oslo, Norway
  • Floortje Mols Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands
  • Unn-Merete Fagerli Department of Oncology, St. Olav’s Hospital, Trondheim, Norway; Department of Cancer Research and Molecular Medicine, NTNU, Trondheim, Norway
  • Hanne S. Bersvendsen Department of Oncology, University Hospital of North Norway, Tromsø, Norway
  • Cecilie E. Kiserud National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway
  • Alexander Fosså Department of Oncology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway

DOI:

https://doi.org/10.1080/0284186X.2021.1917776

Keywords:

Adverse effects, chemotherapy-induced peripheral neuropathy, Hodgkin’s lymphoma survivor, cancer survivorship

Abstract

Background

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of Hodgkin’s lymphoma (HL) treatment. We aimed to describe the prevalence of CIPN associated symptoms in long-term HL survivors compared to controls, and determine associated factors, including impact on health-related quality of life (HRQoL).

Material and methods

A questionnaire, including EORTC QLQ-CIPN-20 for CIPN related symptoms and SF-36 for HRQoL, was completed by 303 HL survivors at a median of 16 years after diagnosis. CIPN results were compared to a normative population (n = 606). CIPN associated factors were identified by linear regression analysis.

Results

Total CIPN score and subscores were significantly higher in HL survivors compared to controls. In multivariate analysis of HL survivors, a number of comorbidities (p < 0.001) and female gender (p = 0.05) were significantly associated with more CIPN. No association with disease or treatment factors was found. In a multivariate analysis including survivors and controls, the number of comorbidities (p < 0.001) and caseness (p < 0.001) were significantly associated with more CIPN. In HL survivors higher CIPN score was associated with reduced HRQoL (p < 0.001).

Conclusion

HL survivors more than a decade after treatment report higher neuropathy-related symptom burden than controls, with a negative impact on HRQoL. Symptoms may be related to factors other than neurotoxic chemotherapy.

Downloads

Download data is not yet available.

Downloads

Published

2021-07-03

How to Cite

Eikeland, S. A. ., Smeland, K. B. ., Mols, F. ., Fagerli, U.-M. ., Bersvendsen, H. S. ., Kiserud, C. E. ., & Fosså, A. . (2021). Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin’s lymphoma; symptom burden and quality of life. Acta Oncologica, 60(7), 911–920. https://doi.org/10.1080/0284186X.2021.1917776

Issue

Vol. 60 No. 7 (2021): Acta Oncologica

Section

Articles